Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Palvella Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 0 | 20 | +20 |
| Shares | 0 | 362.3K | +362.3K |
| Value | $0 | $3.57M | +$3.57M |
New holders (20)
Institutions that held Palvella Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BVF Inc | 257,626 | $2.55M | 0.07% |
| Lynx1 Capital Management LP | 43,499 | $426.8K | 0.15% |
| BlackRock Inc. | 12,975 | $127.3K | 0.00% |
| Renaissance Technologies LLC | 11,471 | $112.5K | 0.00% |
| Vanguard Group Inc | 11,342 | $111.3K | 0.00% |
| Acadian Asset Management LLC | 10,827 | $106.0K | 0.00% |
| Geode Capital Management, LLC | 10,623 | $105.0K | 0.00% |
| UBS Group AG | 1,726 | $16.9K | 0.00% |
| Citigroup Inc | 1,108 | $10.9K | 0.00% |
| Tower Research Capital LLC (TRC) | 334 | $3.28K | 0.00% |
| Group One Trading, L.P. | 323 | $3.19K | 0.00% |
| US Bancorp | 158 | $1.55K | 0.00% |
| Morgan Stanley | 82 | $805 | 0.00% |
| Barclays PLC | 63 | $618 | 0.00% |
| Wells Fargo & Company | 60 | $589 | 0.00% |
| JPMorgan Chase & Co | 27 | $267 | 0.00% |
| Bank of America Corp | 13 | $128 | 0.00% |
| Advisor Group Holdings, Inc. | 7 | $69 | 0.00% |
| Allworth Financial LP | 5 | $37 | 0.00% |
| Royal Bank of Canada | 4 | $0 | 0.00% |
Sold out (0)
Institutions that held Palvella Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
None.